Blood-stage疟疾疫苗候选RH5.1/Matrix-M在健康坦桑尼亚成人和儿童中的开放标签、非随机、首次人体、单中心1b期试验
该1b期试验在坦桑尼亚Bagamoyo招募12名成人和48名儿童,评估RH5.1/Matrix-M疫苗的安全性和免疫原性。疫苗耐受性良好,未发现与疫苗相关的严重不良事件,并诱导了抗RH5抗体和体外生长抑制活性。延迟第三剂方案儿童在第三剂后14天抗RH5 IgG中位数最高,所有11名完成全程者稀释后GIA均超过60%。
要点
- RH5.1/Matrix-M在成人和5-17月龄儿童中耐受性良好,无疫苗相关严重不良事件。
- 疫苗诱导RH5特异性T细胞和血清IgG抗体,纯化IgG显示体外生长抑制活性。
- 延迟第三剂方案儿童第三剂后14天抗RH5 IgG中位数723 μg/mL,稀释后GIA中位数88%。
核心结论
- RH5.1/Matrix-M疫苗候选在疟疾流行区成人和5-17月龄儿童中显示可接受的安全性和反应原性。
- 延迟第三剂方案的所有儿童达到先前在非人灵长类中与抗血阶段恶性疟原虫攻击保护相关的GIA水平。
- 这些数据支持该疫苗候选在非洲幼儿中针对临床疟疾的进一步疗效评估。
研究设计与样本
- 非随机、1b期、单中心、剂量递增、年龄递减、首次人体试验。
- 在坦桑尼亚Bagamoyo招募健康成人(18-45岁)和儿童(5-17月龄)。
- 成人组:Adults 10M组在第0、1、2月接种10 μg RH5.1;Adults DFx组在第0、1月接种50 μg、第6月接种10 μg。
- 儿童组:Children 10M组在第0、1、2月接种10 μg;Children 10D组在第0、1、6月接种10 μg;Children DFx组和High Children DFx组接受剂量递增方案。
- 所有RH5.1剂量均配制50 μg Matrix-M佐剂;主要分析纳入至少接种一剂的全部参与者。
主要发现
- 2021年1月25日至2021年4月15日招募12名成人(Adults 10M组6名[50%],Adults DFx组6名[50%])和48名儿童(Children 10M、Children 10D、Children DFx、High Children DFx组各12名)。
- 60名参与者中57名(95%)完成疫苗接种系列,55名(92%)完成第三剂后22个月随访。
- 试验期间发生5例严重不良事件涉及4名儿童参与者,均判定与疫苗接种无关。
- 所有年龄组和给药方案在末次接种后14天的功能质量(即每μg RH5特异性IgG的GIA)相似;产生50% GIA所需的RH5.1特异性多克隆IgG浓度为14.3 μg/mL(95% CI 13.4-15.2)。
- 11名儿童接种延迟第三剂方案,第三剂后14天抗RH5血清IgG中位数最高(723 μg/mL [IQR 511-1000]),全部11名完成全程者总IgG稀释至2.5 mg/mL后GIA均大于60%(中位数88% [IQR 81-94])。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A blood-stage Plasmodium falciparum malaria vaccine would provide a second line of defence to complement partially effective or waning immunity conferred by the approved pre-erythrocytic vaccines. RH5.1 is a soluble protein vaccine candidate for blood-stage P falciparum, formulated with Matrix-M adjuvant to assess safety and immunogenicity in a malaria-endemic adult and paediatric population for the first time. METHODS: We did a non-randomised, phase 1b, single-centre, dose-escalation, age de-escalation, first-in-human trial of RH5.1/Matrix-M in Bagamoyo, Tanzania. We recruited healthy adults (aged 18-45 years) and children (aged 5-17 months) to receive the RH5.1/Matrix-M vaccine candidate in the following three-dose regimens: 10 μg RH5.1 at 0, 1, and 2 months (Adults 10M), and the higher dose of 50 μg RH5.1 at 0 and 1 month and 10 μg RH5.1 at 6 months (delayed-fractional third dose regimen; Adults DFx). Children received either 10 μg RH5.1 at 0, 1, and 2 months (Children 10M) or 10 μg RH5.1 at 0, 1, and 6 months (delayed third dose regimen; Children 10D), and were recruited in parallel, followed by children who received the dose-escalation regimen (Children DFx) and children with higher malaria pre-exposure who also received the dose-escalation regimen (High Children DFx). All RH5.1 doses were formulated with 50 μg Matrix-M adjuvant. Primary outcomes for vaccine safety were solicited and unsolicited adverse events after each vaccination, along with any serious adverse events during the study period. The secondary outcome measures for immunogenicity were the concentration and avidity of anti-RH5.1 serum IgG antibodies and their percentage growth inhibition activity (GIA) in vitro, as well as cellular immunogenicity to RH5.1. All participants receiving at least one dose of vaccine were included in the primary analyses. This trial is registered at ClinicalTrials.gov, NCT04318002, and is now complete. FINDINGS: Between Jan 25, 2021, and April 15, 2021, we recruited 12 adults (six [50%] in the Adults 10M group and six [50%] in the Adults DFx group) and 48 children (12 each in the Children 10M, Children 10D, Children DFx, and High Children DFx groups). 57 (95%) of 60 participants completed the vaccination series and 55 (92%) completed 22 months of follow-up following the third vaccination. Vaccinations were well-tolerated across both age groups. There were five serious adverse events involving four child participants during the trial, none of which were deemed related to vaccination. RH5-specific T cell and serum IgG antibody responses were induced by vaccination and purified total IgG showed in vitro GIA against P falciparum. We found similar functional quality (ie, GIA per μg RH5-specific IgG) across all age groups and dosing regimens at 14 days after the final vaccination; the concentration of RH5.1-specific polyclonal IgG required to give 50% GIA was 14·3 μg/mL (95% CI 13·4-15·2). 11 children were vaccinated with the delayed third dose regimen and showed the highest median anti-RH5 serum IgG concentration 14 days following the third vaccination (723 μg/mL [IQR 511-1000]), resulting in all 11 who received the full series showing greater than 60% GIA following dilution of total IgG to 2·5 mg/mL (median 88% [IQR 81-94]). INTERPRETATION: The RH5.1/Matrix-M vaccine candidate shows an acceptable safety and reactogenicity profile in both adults and 5-17-month-old children residing in a malaria-endemic area, with all children in the delayed third dose regimen reaching a level of GIA previously associated with protective outcome against blood-stage P falciparum challenge in non-human primates. These data support onward efficacy assessment of this vaccine candidate against clinical malaria in young African children. FUNDING: The European and Developing Countries Clinical Trials Partnership; the UK Medical Research Council; the UK Department for International Development; the National Institute for Health and Care Research Oxford Biomedical Research Centre; the Division of Intramural Research, National Institute of Allergy and Infectious Diseases; the US Agency for International Development; and the Wellcome Trust.
引用
- Silk SE, Kalinga WF, Salkeld J, et al. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial. Lancet Infect Dis. 2024. PMID: 38880111. doi:10.1016/S1473-3099(24)00312-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。